Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 19/20 | 0.63 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.46 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.41 |
| ▸ | APP | P05067 | 2/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.37 |
| ▸ | CTSD | P07339 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL932046 | 0.89 | BACE1 (0.60) | BACE1KCNH2BACE2APPCTSD | |
| SCHEMBL932108 | 0.85 | BACE1 (0.62) | BACE1KCNH2BACE2APPCTSD | |
| SCHEMBL932706 | 0.84 | BACE1 (0.66) | BACE1KCNH2BACE2APPCTSD | |
| SCHEMBL932144 | 0.84 | BACE1 (0.46) | BACE1KCNH2NPY5RCTSD | |
| SCHEMBL932646 | 0.83 | BACE1 (0.46) | BACE1KCNH2NPY5RCTSD | |
| SCHEMBL932844 | 0.83 | BACE1 (0.50) | BACE1KCNH2BACE2CTSD | |
| SCHEMBL932111 | 0.82 | BACE1 (0.47) | BACE1KCNH2BACE2APPCTSD | |
| SCHEMBL932503 | 0.80 | BACE1 (0.67) | BACE1KCNH2BACE2CTSD | |
| SCHEMBL932757 | 0.79 | BACE1 (0.44) | BACE1KCNH2BACE2APPCTSD | |
| SCHEMBL946979 | 0.79 | BACE1 (0.42) | BACE1KCNH2BACE2APPCTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011002407-A1 | NOVEL COMPOUNDS FOR TREATMENT OF NEURODEGENERATION ASSOCIATED WITH DISEASES, SUCH AS ALZHEIMER'S DISEASE OR DEMENTIA | ASTRAZENECA AB (SE) | 2011-01-06 | — | — | WO | disclosed |
| WO-2011002407-A1 | NOVEL COMPOUNDS FOR TREATMENT OF NEURODEGENERATION ASSOCIATED WITH DISEASES, SUCH AS ALZHEIMER'S DISEASE OR DEMENTIA | ASTRAZENECA AB (SE) | 2011-01-06 | — | — | WO | disclosed |